Mitsubishi Tanabe takes Korean company to court as licensing deal turns sour

10 April 2018

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) has filed a request for arbitration against Kolon Life Science (Kosdaq: 102940), a South Korean company that until last month was called TissueGene.

The claim, made in the International Court of Arbitration of the International Chamber of Commerce, is for the return of the upfront sum that Mitsubishi paid as part of the licensing agreement between the two companies for Invossa.

This cell therapy is Kolon’s lead product candidate and is for osteoarthritis of the knee. It has completed Phase II trials in the USA and has attained marketing approval in Korea.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK